Alnylam Pharmaceuticals, Inc. has experienced noteworthy changes in its investor landscape, particularly during the fourth quarter. Allspring Global Investments Holdings LLC has reduced its stake in the company by 10.3%, selling off 32,147 shares. By the end of the quarter, Allspring held approximately 278,657 shares, translating to a value of $111.5 million, which constitutes around 0.21% of Alnylam’s total shares.
Institutional Investment Trends
The shift in Allspring’s position is part of a broader trend among institutional investors. Groupama Asset Management notably increased its holdings in Alnylam by a staggering 160.4% during the third quarter, acquiring an additional 2.48 million shares. This brought their total to over 4 million shares valued at approximately $18.6 million.
Similarly, Arrowstreet Capital Limited Partnership made significant moves, boosting its stake by 698.8%, resulting in ownership of 1.36 million shares valued at about $618.2 million. Other institutions, such as Qube Research & Technologies Ltd and Holocene Advisors LP, have also established or expanded their positions, indicating a strong institutional interest in the biopharmaceutical sector.
Insider Trading Overview
Recent insider trading activity at Alnylam has also garnered attention. CEO Yvonne Greenstreet sold 6,799 shares on March 2 at an average price of $327.65, totaling approximately $2.23 million. This sale reduced her ownership by 6.45%, leaving her with about 98,628 shares valued at over $32.3 million. Similarly, EVP Pushkal Garg sold 1,775 shares a day later, diminishing his stake by 7.05%. Collectively, insiders have offloaded nearly 54,000 shares worth around $18.1 million over the past quarter.
Analyst Ratings and Price Targets
Analysts have been actively evaluating Alnylam’s stock amid these developments. Chardan Capital reaffirmed a “buy” rating with a price target of $425. Bank of America echoed this sentiment, maintaining a “buy” rating. Meanwhile, Weiss Ratings upgraded Alnylam’s stock from “sell” to “hold.” Canaccord Genuity increased its price target from $415 to $429, while Needham & Company adjusted theirs downward from $529 to $510.
Overall, analysts have issued a consensus rating of “Moderate Buy” with a target price of approximately $473.87. The stock has garnered significant attention, with one analyst giving it a “Strong Buy” rating, nineteen recommending a “Buy,” and six suggesting a “Hold.”
Market Performance Insights
Alnylam’s stock opened at $330.71 recently, reflecting a market capitalization of $43.86 billion. The stock has demonstrated volatility, with a 12-month low of $205.87 and a high of $495.55. Financial ratios indicate a debt-to-equity ratio of 1.28, a current ratio of 2.76, and a quick ratio of 2.71. Its performance metrics show a P/E ratio of 193.40 and a beta of 0.36, highlighting its relative stability compared to the market.
In its latest earnings report, Alnylam missed analysts’ expectations for earnings per share, reporting $1.25 instead of the anticipated $1.43. Despite this, the company achieved a remarkable revenue of $1.10 billion for the quarter, up 84.9% year-over-year.
Future Earnings Projections
Looking ahead, analysts project earnings per share of -1.7 for the current year. This forecast suggests challenges in maintaining profitability, yet Alnylam’s continuous investment in research and development positions it favorably within the RNA interference therapeutics market.
Alnylam’s Strategic Focus
Alnylam Pharmaceuticals specializes in developing RNA interference (RNAi) therapeutics, utilizing small interfering RNA (siRNA) technology to target disease-causing genes. The company aims to address a spectrum of both rare and prevalent conditions, delivering durable disease modification through innovative approaches. Their recent advancements include the use of GalNAc-conjugate chemistry for targeted liver delivery, marking a significant step in their therapeutic offerings.
Key Takeaways:
- Allspring Global Investments has reduced its stake in Alnylam Pharmaceuticals, while other institutions have increased their holdings.
- Recent insider sales signal a potential shift in confidence among company executives.
-
Analysts maintain a “Moderate Buy” consensus rating, with several institutions reaffirming their positive outlook on the stock.
-
Alnylam’s financial performance shows significant revenue growth despite missing earnings expectations.
-
The company’s ongoing focus on RNAi therapeutics positions it as a key player in the biopharmaceutical landscape.
In conclusion, Alnylam Pharmaceuticals is navigating a dynamic investment environment marked by shifting institutional interests and proactive management strategies. As the company continues to innovate and expand its therapeutic offerings, its market presence is likely to evolve, making it a focal point for investors and analysts alike.
Read more → www.marketbeat.com